SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Eris Lifesciences - Quaterly Results

13 Feb 2024 Evaluate
Revenue reduced marginally to stand at Rs. 3244.14 millions during the quarter ended December 2023. The figure stood at Rs. 3320.12 millions during the year-ago period.Net profit of the cmpany stood at Rs. 316.55 millions for the quarter ended December 2023 a decline of -68.15% from Rs. 993.79 millions  in the same quarter last year.Operating Profit reported a sharp decline to 778.67 millions from 1298.68 millions in the corresponding previous quarter.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202312 202212 % Var 202312 202212 % Var 202303 202203 % Var
Sales 3244.14 3320.12 -2.29 11454.10 10161.41 12.72 13307.25 12157.30 9.46
Other Income 34.33 34.79 -1.32 144.34 130.04 11.00 172.64 289.89 -40.45
PBIDT 778.67 1298.68 -40.04 3888.60 4066.28 -4.37 5223.78 5129.84 1.83
Interest 151.41 31.42 381.89 285.28 178.54 59.78 208.10 29.91 595.75
PBDT 627.26 1267.26 -50.50 3603.32 3887.74 -7.32 5015.68 5099.93 -1.65
Depreciation 280.83 164.97 70.23 732.47 473.73 54.62 646.57 514.55 25.66
PBT 346.43 1102.29 -68.57 2870.85 3414.01 -15.91 4369.11 4585.38 -4.72
TAX 29.88 108.50 -72.46 268.81 312.34 -13.94 389.03 413.46 -5.91
Deferred Tax -28.44 -83.77 -66.05 -225.26 -282.57 -20.28 -375.93 -388.26 -3.18
PAT 316.55 993.79 -68.15 2602.04 3101.67 -16.11 3980.08 4171.92 -4.60
Equity 136.03 135.99 0.03 136.03 135.99 0.03 135.99 135.93 0.04
PBIDTM(%) 24.00 39.12 -38.64 33.95 40.02 -15.16 39.26 42.20 -6.97

Eris Lifesciences Share Price

1446.50 -18.90 (-1.29%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×